• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ISTA wins branding award for launch of ophthalmic solution

Article

The Healthcare Distribution Management Association (HDMA), Arlington, VA, named the launch of bromfenac sodium ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals, Irvine, CA) as the Best New Branded Pharmaceutical Product Introduction and/or Product Promotion.

The topical ophthalmic, non-steroidal anti-inflammatory compound treats ocular inflammation following cataract surgery. The FDA approved the drug in March 2005 and it was launched in the second quarter of this year.

HDMA announced its Distribution Industry Awards for Notable Achievements in Healthcare (DIANA) during the association's annual leadership forum. The award is presented to pharmaceutical and consumer product manufacturers that set the standard of excellence in new product introductions, product promotions, and overall business practices with HDMA health-care distributors.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.